Skip to main content

Table 3 Clinical and demographic characteristics in patients with and without HCC occurrence—univariate and multivariate analysis

From: Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

Parameters Univariate analysis Multivariate analysis (cirrhosis) Multivariate analysis (Child–Pugh)
Patients without HCC (n = 950) Patients with HCC (n = 35) p O.R. [95% C.I.] p O.R. [95% C.I.] p
Male gender, n (%) 518 (54.5) 25 (71.4) 0.048 2.852 [1.162–6.999] 0.022 2.738 [1.109–6.762] 0.029
Age, years, median [IQR] 67 [59–73] 69 [64–74] 0.045     
BMI, kg/m2, median [IQR] 26 [24–28.4] 25.4 [23.4–28] 0.17     
Presence of diabetes, n (%) 121 (12.8) 10 (28.6) 0.007 0.392 [0.155–0.988] 0.047 0.369 [0.146–0.931] 0.047
Presence of cirrhosis, n (%) 696 (73.4) 35 (100) 0.002 0.153 [0.019–1.239] 0.079   
CTP B classa n (%) 72/696 (10.3) 10/34 (29.4) 0.001    0.430 [0.170–1.086] 0.074
HCV genotype 1, n (%) 724 (77.3) 29 (82.9) 0.44     
24 weeks treatment duration, n (%) 354 (37.3) 19 (54.3) 0.041     
Baseline HCV-RNA, UI/ml, median [IQR] 995,500 [350,000–2,646,500] 729,000 [290,000–1,238,000] 0.123     
Liver stiffness, kPa, median [IQR] 14.9 [11.8–22] 32 [18.5–44.4] < 0.0001 1.048 [1.020–1.077] 0.001 1.057 [1.031–1.084] 0.000
SVR12, n (%) 933 (98.2) 33 (94.3) 0.09     
DAA-SOF based, n (%) 707 (74.6) 31 (88.6) 0.09     
DAA-RBV included, n (%) 690 (72.8) 15 (42.9) < 0.0001     
DAA-SOF + RBV, n (%) 562 (59.2) 12 (34.3) 0.003     
DAA-SOF without RBV, n (%) 145 (20.5) 19 (61.3) 0.003 15.363 [6.668–35.396] 0.000 0.059 [0.025–0.137] 0.000
  1. aComputed based on number of cirrhotic patients
\